Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05872867 2024-03-12

MK-3475-E90

Phase 1 Unknown

54 enrolled

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06307093 2024-03-12

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

Phase 1 Unknown

90 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Lung Neoplasms, Melanoma, Neoplasms

Clinical Trials

KeyPemls-004

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

MK-3475-E90

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

I-STOP

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

LUCACRIMUNO

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

MiST

Microbiome Immunotherapy Toxicity and Response Evaluation

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

Luscid

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

DYNAPET

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Pembrolizumab + CVA21 in Advanced NSCLC

PEOPLE

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

NO3DEXPL

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients